July 23, 2025NanomaterialsOpen Access

Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

View Full Paper

Ask AI

Bookmark

Authors

IPIris Pontón DSDavid Sánchez‐GarcíaInstitut Químic de Sarrià

Discussion

Member takes

Implication

This review highlights how nanocarriers enhance efficacy in pancreatic ductal adenocarcinoma combination therapy, suggesting a solution to multidrug resistance.

Key Points

Pancreatic ductal adenocarcinoma is a highly lethal cancer with poor response to standard treatment options.
Combination therapy shows promise by overcoming multidrug resistance and effectively targeting the tumor microenvironment.
Nanoparticle-based drug delivery systems are designed to co-deliver therapies with controlled release profiles, enhancing treatment potential.
This review discusses advancements in nanoparticle platforms for PDAC therapies published over a 20-year span, from 2005 to 2025.

Cite This Study

Pontón et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cda8f https://doi.org/10.3390/nano15151139

View Full Paper

Ask AI

Bookmark

Implication

This review highlights how nanocarriers enhance efficacy in pancreatic ductal adenocarcinoma combination therapy, suggesting a solution to multidrug resistance.

Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

Discussion

Member takes

Implication

Key Points

Cite This Study

Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider